JP2015529684A - アンジオテンシンの経口製剤 - Google Patents

アンジオテンシンの経口製剤 Download PDF

Info

Publication number
JP2015529684A
JP2015529684A JP2015532144A JP2015532144A JP2015529684A JP 2015529684 A JP2015529684 A JP 2015529684A JP 2015532144 A JP2015532144 A JP 2015532144A JP 2015532144 A JP2015532144 A JP 2015532144A JP 2015529684 A JP2015529684 A JP 2015529684A
Authority
JP
Japan
Prior art keywords
dosage form
solid dosage
angiotensin
peptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015532144A
Other languages
English (en)
Japanese (ja)
Inventor
リチャード フランクリン，
リチャード フランクリン，
ウィリアム スターン，
ウィリアム スターン，
オースティン ブライホフ，
オースティン ブライホフ，
Original Assignee
タリックス ファーマシューティカルズ リミテッド
タリックス ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリックス ファーマシューティカルズ リミテッド, タリックス ファーマシューティカルズ リミテッド filed Critical タリックス ファーマシューティカルズ リミテッド
Publication of JP2015529684A publication Critical patent/JP2015529684A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2015532144A 2012-09-17 2013-09-17 アンジオテンシンの経口製剤 Pending JP2015529684A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701972P 2012-09-17 2012-09-17
US61/701,972 2012-09-17
PCT/US2013/060139 WO2014043693A1 (en) 2012-09-17 2013-09-17 Oral formulations of angiotensin

Publications (1)

Publication Number Publication Date
JP2015529684A true JP2015529684A (ja) 2015-10-08

Family

ID=50278763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532144A Pending JP2015529684A (ja) 2012-09-17 2013-09-17 アンジオテンシンの経口製剤

Country Status (13)

Country Link
US (1) US20150246093A1 (hu)
EP (1) EP2895154A4 (hu)
JP (1) JP2015529684A (hu)
KR (1) KR20150065736A (hu)
CN (1) CN104853749A (hu)
AU (1) AU2013315004A1 (hu)
BR (1) BR112015005738A2 (hu)
CA (1) CA2884792A1 (hu)
HK (1) HK1213785A1 (hu)
IN (1) IN2015DN03132A (hu)
MX (1) MX2015003407A (hu)
RU (1) RU2015108678A (hu)
WO (1) WO2014043693A1 (hu)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023063376A1 (ja) * 2021-10-13 2023-04-20 中外製薬株式会社 ペプチド化合物及び界面活性剤を含む組成物
WO2023214509A1 (ja) * 2022-05-02 2023-11-09 中外製薬株式会社 界面活性剤と併用するためのペプチド化合物を含む組成物
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115082A1 (en) * 2015-01-12 2016-07-21 Enteris Biopharma, Inc. Solid oral dosage forms
WO2017049140A2 (en) * 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7375073B2 (en) * 2002-02-27 2008-05-20 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
US20080199434A1 (en) * 2006-11-13 2008-08-21 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of cardiovascular conditions
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
BRPI0800585B8 (pt) * 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
RU2589823C2 (ru) * 2009-04-09 2016-07-10 Алкермес Фарма Айэленд Лимитед Композиция для доставки лекарственных средств
PT2536422E (pt) * 2011-02-02 2014-07-18 Univ Southern California Métodos para o tratamento de úlceras do pé diabético

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023063376A1 (ja) * 2021-10-13 2023-04-20 中外製薬株式会社 ペプチド化合物及び界面活性剤を含む組成物
WO2023214509A1 (ja) * 2022-05-02 2023-11-09 中外製薬株式会社 界面活性剤と併用するためのペプチド化合物を含む組成物
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Also Published As

Publication number Publication date
EP2895154A4 (en) 2016-04-20
HK1213785A1 (zh) 2016-07-15
CN104853749A (zh) 2015-08-19
KR20150065736A (ko) 2015-06-15
US20150246093A1 (en) 2015-09-03
RU2015108678A (ru) 2016-11-10
MX2015003407A (es) 2015-10-14
IN2015DN03132A (hu) 2015-10-02
EP2895154A1 (en) 2015-07-22
WO2014043693A1 (en) 2014-03-20
CA2884792A1 (en) 2014-03-20
AU2013315004A1 (en) 2015-04-02
BR112015005738A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
JP6302916B2 (ja) 脳状態の処置におけるアンジオテンシン
EP2819687A1 (en) Compositions and methods for treatment of peripheral vascular disease
JP2015529684A (ja) アンジオテンシンの経口製剤
US20230110554A1 (en) Methods and compositions for treatment of coronavirus infection
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
WO2013192238A2 (en) Compositions and methods for treatment of diabetes
US20180221433A1 (en) Angiotensins in muscular dystrophy
AU2014332346B2 (en) Novel peptide compositions
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
US9133241B2 (en) Peptide compositions
US20200188473A1 (en) Combination therapy for cancer